Free Trial

OMERS ADMINISTRATION Corp Grows Stake in Exelon Co. (NASDAQ:EXC)

Exelon logo with Utilities background

OMERS ADMINISTRATION Corp raised its holdings in Exelon Co. (NASDAQ:EXC - Free Report) by 20.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 41,603 shares of the company's stock after buying an additional 7,070 shares during the quarter. OMERS ADMINISTRATION Corp's holdings in Exelon were worth $1,566,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Robeco Institutional Asset Management B.V. lifted its stake in Exelon by 20.8% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 1,624,805 shares of the company's stock valued at $61,158,000 after acquiring an additional 279,827 shares in the last quarter. Greenup Street Wealth Management LLC bought a new position in shares of Exelon during the fourth quarter valued at about $2,274,000. Principal Securities Inc. lifted its position in shares of Exelon by 10.6% during the fourth quarter. Principal Securities Inc. now owns 22,612 shares of the company's stock valued at $851,000 after purchasing an additional 2,160 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in Exelon by 212.2% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,903,482 shares of the company's stock valued at $71,647,000 after buying an additional 1,293,753 shares during the last quarter. Finally, Busey Bank increased its stake in Exelon by 4.0% in the 4th quarter. Busey Bank now owns 326,105 shares of the company's stock valued at $12,275,000 after buying an additional 12,530 shares during the last quarter. 80.92% of the stock is owned by institutional investors.

Exelon Price Performance

EXC traded down $0.02 during midday trading on Wednesday, hitting $44.25. The stock had a trading volume of 2,100,726 shares, compared to its average volume of 7,269,875. Exelon Co. has a 1 year low of $34.01 and a 1 year high of $48.11. The company has a market cap of $44.67 billion, a P/E ratio of 18.07, a price-to-earnings-growth ratio of 2.86 and a beta of 0.43. The business has a fifty day moving average of $45.28 and a 200 day moving average of $41.64. The company has a debt-to-equity ratio of 1.61, a quick ratio of 0.78 and a current ratio of 0.87.

Exelon (NASDAQ:EXC - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.86 by $0.06. The firm had revenue of $6.71 billion for the quarter, compared to analysts' expectations of $6.30 billion. Exelon had a net margin of 10.68% and a return on equity of 9.52%. The business's revenue was up 11.1% on a year-over-year basis. During the same quarter last year, the business earned $0.68 earnings per share. As a group, equities analysts forecast that Exelon Co. will post 2.64 earnings per share for the current fiscal year.

Exelon Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Monday, May 12th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.62%. The ex-dividend date of this dividend is Monday, May 12th. Exelon's dividend payout ratio (DPR) is presently 59.48%.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on EXC shares. Barclays raised their price objective on shares of Exelon from $42.00 to $48.00 and gave the stock an "overweight" rating in a report on Tuesday, February 25th. Evercore ISI raised their price target on shares of Exelon from $48.00 to $51.00 and gave the stock an "in-line" rating in a research note on Friday, May 2nd. Guggenheim upped their price objective on Exelon from $47.00 to $50.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Morgan Stanley upped their price target on Exelon from $46.00 to $48.00 and gave the company an "equal weight" rating in a research report on Thursday, March 20th. Finally, KeyCorp lowered shares of Exelon from a "sector weight" rating to an "underweight" rating and set a $39.00 target price for the company. in a research report on Wednesday, May 14th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $47.30.

Read Our Latest Research Report on Exelon

Exelon Company Profile

(Free Report)

Exelon Corporation, a utility services holding company, engages in the energy distribution and transmission businesses in the United States and Canada. The company is involved in the purchase and regulated retail sale of electricity and natural gas, transmission and distribution of electricity, and distribution of natural gas to retail customers.

Read More

Institutional Ownership by Quarter for Exelon (NASDAQ:EXC)

Should You Invest $1,000 in Exelon Right Now?

Before you consider Exelon, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelon wasn't on the list.

While Exelon currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

This $13 Trillion Energy Breakthrough Will Make Millionaires
Magnificent 7 Stocks Shift Toward Stability and Selective Growth
4 Biotech Stocks on the Verge of Massive Breakthroughs

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines